ImmuneOncia aims to develop immuno-oncology therapeutics

to transform the standard of care in cancer treatment

  • About Us
  • Overview

Overview

Changing the Standard
of cancer treatment
By Bringing Korea’s
1st Immuno-oncology Drug

As a global pharmaceutical and biotech company, ImmuneOncia's vision is to redefine cancer therapy by developing innovative immuno-oncology therapeutics.

Since its establishment in 2016, ImmuneOncia has been dedicated to supplying safe, effective, and innovative new drugs to cancer patients worldwide, leveraging its expertise in preclinical and clinical drug development as well as antibody engineering.

ImmuneOncia is advancing the development of its best-in-class antibodies, IMC-001 and IMC-002, which target the fundamental axes of immuno-oncology therapy: T-cells and macrophages. We are also pursuing the development of bispecific antibodies, which are expected to become a cornerstone of future immuno-oncology. Additionally, we have a strategic plan to develop Antibody-Drug Conjugates (ADCs), leveraging our antibody platforms, as we strive to become a leader in innovative therapies.

  • A Clinical-Stage biopharmaceutical company focused on immuno-oncology
  • Leveraging expertise in drug Development and antibody engineering
  • Dedicated to delivering safe, effective, and innovative immunotherapies to cancer patients globally